PharmaShots | Incisive News in 3 Shots

Subscribe Now

tisagenlecleucel

Novartis' Kymriah (tisagenlecleucel) Fails to Meet its Primary Endpoint in P-III BELINDA Study as 2L Treatment in Aggressive B-Cell Non-Hodgkin Lymphoma

Novartis' Kymriah (tisagenlecleucel) Fails to Meet its Primary Endpoint in P-III BELINDA Study as 2L Treatment in Aggressive B-Cel...

August 24, 2021

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

August 4, 2020

Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma

Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymph...

April 22, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us